NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP
Cerus Corporation CERS
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$233.8M
▲ 16.1% vs FY2024
EPS · FY25
$-0.08
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-26.0%
Net margin · FY25
-6.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 233.8M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 7 cents on every revenue dollar this year.
Per share
USD -0.08
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-26.0%
Return on equity, FY2025
ROE
Operating margin-3.7%
Net margin-6.7%
Return on assets-7.4%
Each USD of equity lost 26 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+15.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.5%
+15.4%
+21.2%
+17.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years+14.3%
Change, 10 years+93.9%
The share count grew 14% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 221.9M
total assets, end of FY2025
Total assetsUSD 221.9M
EquityUSD 64.2M
CashUSD 20.0M
Gross debtUSD 83.9M
Net debtUSD 63.9M
Current ratio1.73×
Net debt stands at 100% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.08
−0.11
−0.21
−0.24
−0.32
−0.37
−0.51
−0.44
−0.56
−0.62
−0.61
−0.61
−0.64
−0.33
−0.35
−0.42
−0.69
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−26.0
−38.5
−62.3
−56.2
−57.7
−74.4
−100.6
−93.3
−125.3
−82.5
−82.0
−91.9
−140.0
−85.1
−80.8
−74.9
−112.5
Shares out B
0.19
0.19
0.18
0.18
0.17
0.17
0.14
0.14
0.12
0.10
0.10
0.08
0.07
0.06
0.05
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed